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A substantial part of the contribution of genetic studies to
the treatment of schizophrenia involves its emphasis on
reliable and valid diagnoses. One consequence of this
focus is the recognition that schizophrenic illness is
broader than the diagnostic entity of schizophrenia itself,
and instead consists of a “spectrum” of related disorders.
Because some of the symptoms in these disorders differ
from each other, they provide an opportunity to deter-
mine which ones reflect a common etiology. To the extent
that such symptoms are identifiable, they may provide a
foundation for treatment and even prevention strategies.
In this paper, we focus on a clinical condition—“schizo-
taxia”—that may reflect the liability for schizophrenia.
To characterize the nature and extent of this proposed
syndrome, we will review results from family studies in
our laboratory, and consider conceptual foundations and
criteria for assessment. A more general consideration of
treatment strategies for schizophrenia spectrum disorders
follows, along with suggestions for future research. Our
initial attempts to treat and validate schizotaxia are
encouraging, and raise the possibility that early treatment
might eventually prevent or attenuate the development
of other, more severe disorders in the schizophrenia spec-
trum, including schizophrenia itself.
t is over 100 years since Kraepelin delineated
dementia praecox from manic depressive psychoses,
1
and nearly that long since Bleuler reformulated schizo-
phrenia from dementia praecox.
2 In that time, progress
toward effective treatments for schizophrenia has been
slow,but tangible.At least three sources of progress are
clearly identifiable.First,and most generally,treatments
for schizophrenia and other mental illnesses have
became more humane,and are now aligned more closely
(although not closely enough) with treatments for other
medical problems than used to be the case. Second,
antipsychotic medications have become a first line of
defense, and have improved the lives of most patients.
This is particularly true of the newer generation of phar-
maceutical agents.
Third, a greater understanding of the genetic basis of
schizophrenia underlies much of our recent progress,in
part through its focus on reliable and valid diagnoses.
This paper will focus on one consequence of genetic
studies, which is the recognition that schizophrenic ill-
ness is broader than the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM) or International Classi-
fication of Diseases (ICD) diagnoses of schizophrenia,
and exists as a “spectrum” of conditions. While some
spectrum disorders are nearly as severe as schizophrenia
(eg, schizoaffective disorder), others are milder and do
not involve psychosis (eg,schizotypal personality disor-
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Clinical researchder [SPD]).The spectrum concept has numerous impli-
cations for treatment. For example, therapeutic efforts
vary across schizophrenia spectrum disorders as func-
tions of both the severity and the type of symptoms.
These differences are of great importance in under-
standing the core features of schizophrenic conditions.
In particular, the fact that psychosis is not a major fea-
ture of all schizophrenia spectrum disorders suggests
that other, more subtle symptoms might better reflect
the underlying etiology of schizophrenic illness,through-
out the associated spectrum of disorders.If such deficits
are identifiable,they may provide a foundation for treat-
ment strategies. Moreover, if they are identified early,
they may even prevent psychosis.
The discussion of spectrum disorders here will focus on
symptoms that may reflect the genetic predisposition
for schizophrenia. We reformulated Meehl’s notion of
“schizotaxia”recently to describe this liability,
3-5 and will
review here studies conducted in our laboratory with
nonpsychotic relatives of schizophrenic patients to con-
ceptualize the nature and extent of this proposed syn-
drome. With schizotaxia in mind as a core liability for
schizophrenia and other spectrum conditions, we will
then consider treatments for spectrum disorders more
generally,and directions for future research.
Lessons from family studies of nonpsychotic
relatives of schizophrenic patients
Over the last 15 years, we have made steady progress
toward the identification of neuropsychological and
structural brain abnormalities among schizophrenic
patients and their nonpsychotic first-degree relatives.
Through the implementation of ongoing family studies,
these data show:(i) the relatively specific neuropsycho-
logical deficits in schizophrenic patients and their rela-
tives;(ii) the stability of these deficits over time;(iii) the
structural and functional brain abnormalities in patients
and relatives; and (iv) the effects of genetic loading on
neuropsychological functions and neuroanatomical
structures.These findings,which form the foundation of
current efforts to define,validate,and treat schizotaxia,
are described next.
Neuropsychological function among adult relatives
In an initial study, Faraone et al assessed neuropsy-
chological functioning in 35 nonpsychotic adult rela-
tives of schizophrenic patients and 72 normal controls.
6
We used linear combinations of neuropsychological
tests to create scales assessing 10 neuropsychological
functions: abstraction/executive function, verbal abili-
ty,spatial ability,verbal memory,visual memory,learn-
ing,perceptual-motor speed,mental control/encoding,
motor function, and auditory attention. Based on pre-
vious neuropsychological studies of patients with schiz-
ophrenia and our review of family studies,
7 we predict-
ed that relatives of patients with schizophrenia would
exhibit deficits in abstraction/executive function,learn-
ing and memory, and components of attention (per-
ceptual/motor speed,mental control/encoding,and vig-
ilance).
A multivariate analysis of variance found the neuropsy-
chological profile of the relatives to be significantly more
impaired than the control profile. The relatives per-
formed more poorly and had greater variability on the
three predicted functions: abstraction/executive func-
tion, verbal memory, and auditory attention/vigilance.
They had lower mean scores, but similar variability on
verbal ability and mental control/encoding.They showed
more variability, but not lower mean scores, on learn-
ing and motor abilities.The two groups did not differ in
terms of visual/spatial ability,visual memory,or percep-
tual/motor function. The deficits observed were not
accounted for by psychopathology in the relatives, by
level of education,or by parental social class.
Because we did not study psychotic relatives, and only
one of the relatives in our sample had SPD, we con-
cluded that neuropsychological measures might be use-
ful in detecting putative carriers of the schizophrenia
genotype, who cannot be detected with psychiatric
assessments.Our findings also led to the hypothesis that,
if the expression of neuropsychological risk indicators in
the relatives was due to an underlying genotype not pre-
sent in the controls,then the neuropsychological indica-
tors of the schizophrenia genotype would intercorrelate
to a greater degree within the relative group than within
the control group.
8At the time of this more recent analy-
sis, the sample had increased to 54 relatives of patients
with schizophrenia. In the larger sample, the relatives
continued to display significantly lower mean scores
than the control group on abstraction skills, memory
(verbal and visual),and auditory attention.
Within the relative group, we found significant intercor-
relations among skills of abstraction,verbal memory,and
auditory attention, both within and between these func-
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tions.In addition,the significant correlations among rela-
tives between attention and verbal memory and between
attention and abstraction differed significantly from these
correlations in the control group.Thus,the greater level of
cooccurrence between these putative neuropsychologi-
cal risk indicators within the high-risk group provides fur-
ther support for their status as risk indicators of the same
underlying vulnerability to schizophrenia.
Some recent studies
9 suggest that men with schizophrenia
may have greater neuropsychological deficits than women.
It is not known, however, whether similar sex differences
may be present in biological relatives of patients with
schizophrenia. We hypothesized that if sex differences
were present, they would be accounted for largely by
deficits in male relatives.We were particularly interested in
the three neuropsychological functions that we identified
as putative neuropsychological vulnerability indicators for
schizophrenia. In fact, we found significant group-by-sex
interactions for verbal memory and motor function, and
trends toward significant interactions for auditory atten-
tion and mental control/encoding.
9 Notably,with the excep-
tion of motor function, it was the female relatives who
accounted for most of the impairment. A speculative
explanation for the findings is that women may have a
higher threshold than men for developing schizophrenia.If
so, female relatives might be able to withstand greater
impairments than men before developing psychotic symp-
toms. Consequently, in a sample that was limited to
nonpsychotic relatives, there could be overrepresentation
of both less impaired men and more impaired women.
Stability of neuropsychological deficits
The neuropsychological studies discussed thus far used
data from a baseline assessment.These were extended
recently, in two ways.
10 First, by completing a follow-up
study,we tested the hypothesis that neuropsychological
deficits among adult relatives of schizophrenic patients
would be stable over time. Second, with the addition of
new tests of executive functioning,we tested the hypoth-
esis that neuropsychological differences between con-
trols and relatives of schizophrenic patients would be
evident on delayed-response tasks.These tasks are sen-
sitive to working memory, ie, the neuropsychological
function that briefly holds information “on line”for use
in other cognitive tasks such as reasoning. Differences
between the groups included measures of immediate
verbal memory,delayed verbal memory (both from the
logical memory test), and complex attention (dichotic
listening digits detected).Immediate and delayed verbal
and visual memories showed interactions with gender,
but none of the test scores showed group-by-time inter-
actions, showing that the discriminating power of the
tests remained stable over time.As we found at baseline,
the relatives showed significantly poorer performance
than the controls at follow-up.
For one of the additional tests of executive functioning,
object alternation (OA),we found significant effects for
sex and the group-by-sex interaction for the total and
perseverative error scores. The nature of the interac-
tions was the same as we observed at baseline: the
greater impairment of relatives compared with controls
was more pronounced for females than for males.
These results are consistent with the idea that neuro-
psychological dysfunction among relatives of schizo-
phrenic patients is a stable trait that assesses the pre-
disposition to schizophrenia.
Neuroimaging abnormalities
Structural magnetic resonance imaging studies 
In addition to neuropsychological tests, relatives of
patients with schizophrenia show abnormalities in both
specific brain regions and patterns of brain activation.
11 In
a pilot study,
12 we compared 6 female siblings of schizo-
phrenic patients with 11 female controls.Volumes (ie,sizes
of brain structures) were adjusted for total intracranial
volume, which did not differ between the groups. Gray
matter volumes of subcortical structures were smaller and
ventricular volumes were larger among the relatives.Sig-
nificant volume reductions in relatives were found in the
thalamus,the right amygdala,the right pallidum,the right
putamen,and the brain stem.Bilateral inferior lateral ven-
tricles were significantly larger in relatives.
Interestingly, measures of auditory attention correlated
with selected magnetic resonance imaging (MRI) brain
volumes in this preliminary sample. In particular, total
thalamus volume correlated with the ability to suppress
interfering stimuli on two tests (r=0.87 and r=0.80), and
total hippocampal volume correlated with the ability to
handle a working memory load (r=0.89 and r=0.87) and
with Wisconsin card sorting categories (r=0.70). These
preliminary results suggest that interference effects on
sustained attention are strongly associated with thalamus
volume reduction,whereas attention,memory,and prob-
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lem solving are associated with hippocampal volume
reduction.
We recently completed analyses on a larger sample that
includes schizophrenic patients.
13We sought to extend our
pilot study, and to determine which abnormalities char-
acterized schizophrenic patients beyond those we had
identified in the relatives.Subjects were 29 schizophrenic
patients,28 nonpsychotic first-degree adult relatives,and
26 normal controls.The volumes were adjusted for total
cerebral volumes;statistical analyses were controlled for
the effects of sex. Compared with controls, relatives had
significant volume reductions bilaterally in the amygdala-
hippocampal region, the thalamus, and the cerebellum,
and significantly increased volumes in the pallidum.
Patients demonstrated significantly increased volumes in
the lateral and third ventricles,the pallidum,and the right
cerebral white matter.They had significant decreases in
the left thalamus and the right hippocampus. Compared
with relatives, patients had significantly larger putamen
and amygdala-hippocampal regions and smaller cerebral
cortices. Results indicate that nonpsychotic relatives of
schizophrenic patients have abnormal brain structures
that overlap with abnormalities in patients.This supports
the hypothesis that the genetic liability to schizophrenia is
expressed as brain abnormalities in key subcortical struc-
tures,including the thalamus and amygdala-hippocampal
regions.These results are consistent with other studies of
schizophrenic patients,in which third and lateral ventricle
enlargements are the most common findings.
Our MRI data are consistent with the hypothesis that
abnormalities in limbic-diencephalic areas may be core
features of “schizotaxia,” which become amplified by a
second “hit”that alters the cortex,enlarges the third and
lateral ventricles,and leads to schizophrenic illness.From
these data,however,we are unable to determine whether
the abnormalities found in patients reflect only greater
preexisting pathology and thus a greater vulnerability to
illness,or some additional pathology due to the progres-
sion of the illness or other incidental factors (ie, medica-
tions, etc). Eventually, studies of schizotaxia will help
resolve this issue.
Functional MRI studies
In a preliminary study of normal subjects, our primary
goal was to assess the brain activations (ie, brain areas
that become activated) associated with simple and
demanding auditory vigilance tasks, using functional
MRI (fMRI).
14We initially created novel auditory con-
tinuous performance tests (CPTs) in which a demand-
ing working memory task was made more difficult than
a simple vigilance task on the basis of increased work-
ing memory and interference filtering requirements.
Compared with the vigilance task, performance of the
working memory task produced significant signal
changes bilaterally in the lateral prefrontal cortex, the
premotor and frontal eye fields, the parietal-occipital
cortex,the thalamus,the superior colliculus,the insula,
the anterior cingulate, and the temporal lobe, including
the hippocampus.Performance and degree of activation
were associated with an IQ estimate.
We subsequently began a pilot study applying fMRI to
the relatives of schizophrenic patients from our neu-
ropsychology family study.
15Thirteen never-psychotic and
non–spectrum disorder relatives of schizophrenic patients
and 12 matched normal controls were compared.All sub-
jects were less than 55 years of age and had standard
scores on a reading test of at least 80 (ie,at least the low-
normal range). Relatives were significantly impaired on
working memory tasks with interference. The tasks pro-
duced activation in the lateral and medial frontal cortex,
the posterior parietal and precuneal cortex,and the thala-
mus in both groups.The most striking finding from these
data is the difference in the number of regions activated
and the extent of regional activations (number of “vox-
els”) in relatives compared with the controls.Across the
three tasks, the relatives had a greater number of activa-
tions,representing significantly more activated voxels than
the controls.On working memory and memory plus inter-
ference tasks,activation was more bilaterally distributed in
relatives than in controls.As relatives also perform worse
on these cognitive tasks, these large and extraneous acti-
vations in relatives may represent:(i) compensatory exer-
tion of inefficient neural circuitry in attempting to per-
form an effortful task to produce accurate output;and/or
(ii) abnormal connectivity in the circuitry required to per-
form these tasks. These functional data complement the
structural MRI abnormalities and suggest that adult rela-
tives of schizophrenic patients have brain abnormalities,
possibly associated with abnormal genes.
Effects of genetic loading on verbal memory 
and hippocampal volume in relatives
Following up the above findings of stability in measures
of verbal memory and attention in nonpsychotic rela-
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tives of schizophrenic patients,we compared individuals
with one schizophrenic first-degree relative (simplex
families) to individuals with two schizophrenic first-
degree relatives (multiplex families).
16 Relatives from
simplex families performed significantly less well on
immediate memory (from the logical memory test) com-
pared with controls,while relatives from multiplex fam-
ilies performed significantly worse on immediate and
delayed logical memory,immediate visual reproductions,
and estimated intelligence,compared with controls.Rel-
atives from multiplex families also had a significantly
poorer performance than relatives from simplex families
on immediate and delayed logical memories, immedi-
ate visual reproductions, and estimated intelligence.
These results are consistent with the idea that neu-
ropsychological deficits in relatives of patients with
schizophrenia reflect their degree of genetic predisposi-
tion to schizophrenia.This relationship was also evident
in analyses of structural brain volumes. As described
above, relatives show reduced hippocampal volumes
compared with controls.
13,17 More recently, we found
reductions in left (but not right) hippocampal volumes
compared with controls, in both simplex and multiplex
siblings of schizophrenic patients.
18 Multiplex siblings,
however, also showed greater volume reductions than
did simplex siblings. Moreover, better performance on
the logical memory test was significantly correlated with
larger hippocampal volume, especially on the left side,
and especially in multiplex siblings.These data are fur-
ther consistent with the hypothesis that greater degrees
of genetic predisposition to schizophrenia are associ-
ated with neuropsychological (verbal memory) deficits
and neurobiological abnormalities.
The nature of schizotaxia
Conceptual foundations
As noted above,Paul Meehl first used the term “schizo-
taxia” to describe the genetic predisposition to schizo-
phrenia.
3 In his view, schizotaxic individuals would
develop either schizotypy or schizophrenia, depending
on environmental circumstances.For example,relatively
favorable environmental conditions might interact with
the genetic predisposition to produce schizotypy, while
relatively adverse environmental conditions would more
likely lead to schizophrenia. Meehl later modified his
view somewhat to allow for the possibility that in some
cases, schizotaxia might not progress to either schizo-
typy or schizophrenia,but this outcome represented the
exception rather than the rule.
19 Eventually, schizotypy
(in the form of SPD) entered the diagnostic nomencla-
ture, but schizotaxia did not. Instead, it has been used
mainly in research to indicate the premorbid, neurolo-
biological substrate of schizophrenia, but not used to
identify a clinically meaningful syndrome or spectrum
disorder.
Now, almost four decades later, research suggests that
schizotaxia is a clinically consequential condition. A
large body of evidence,including the examples described
in the preceding section, shows abnormalities in affect,
cognition, social functioning, and brain function among
the nonschizotypal and nonpsychotic relatives of schiz-
ophrenic patients.
5 These data show that schizotaxia is
not merely a theoretical construct;it has psychiatric and
neurobiological features that justify further research
about its nosologic validity.
Although our use of the term schizotaxia is consistent
with Meehl’s view of it as the underlying defect among
people genetically predisposed to schizophrenia, we do
not endorse several other aspects of his theory.Among
these, first, is the nature of the genetic etiology of schiz-
ophrenia.For example,having written his theory prior to
the availability of molecular genetic data,Meehl favored
a single major gene theory of schizophrenia, which has
since been falsified by genetic linkage studies. Second,
Meehl viewed schizotaxia solely as the genetic predis-
position to schizophrenia.We view schizotaxia as the pre-
disposition to schizophrenia too, but conceptualize its
etiology to include both genetic and nongenetic biologi-
cal consequences of early adverse environmental cir-
cumstances (eg, pregnancy or delivery complications).
Third,Meehl viewed schizotypy as the only nonpsychotic
clinical expression of schizotaxia.In our view,schizotaxia
is frequently a stable clinical condition that is more
common in relatives of schizophrenic patients than is
schizotypy.We found, for instance, that core symptoms
of schizotaxia characterized 20% and 50% of nonpsy-
chotic relatives of schizophrenic patients in our family
studies.
6,20Thus,schizotaxia does not necessarily progress
into a more severe disorder.
This view of the liability for schizophrenia is consistent
with a neurodevelopmental perspective. In our view,
once schizotaxia develops,it may then interact with later
adverse environmental events (considered broadly,such
as substance abuse, psychosocial stressors, or a headinjury),which impairs brain function further and leads to
psychosis. Psychosis itself is not necessarily caused by
the same factors—genetic or environmental—that cause
schizotaxia, but may reflect more of a nonspecific end-
state that occurs in a variety of severe psychiatric and
neurologic conditions (eg,major depression,severe head
injury,partial complex seizures,Alzheimer’s disease,and
various substance-induced states).If this conceptualiza-
tion of schizotaxia is correct,it may thus be a more spe-
cific expression of the predisposition to schizophrenia
than is the DSM-IV diagnosis of schizophrenia.For this
reason,if schizotaxia is validated as a syndrome,we pro-
posed that the diagnosis of schizophrenia be broadened
into two categories: schizotaxia, and schizotaxia plus
psychosis (ie,schizophrenia).
4
Assessment
Schizotaxia remains an evolving concept, not a disorder
with set criteria.Tsuang et al
21 recently operationalized
research criteria for schizotaxia based on the combination
of negative symptoms and neuropsychological deficits,
which are two of the most robust findings in first-degree
relatives of patients with schizophrenia.
5,22To meet the cri-
teria of  Tsuang et al for schizotaxia, subjects must show
both moderate or higher levels of negative symptoms
(defined as 6 scores rated 3 or higher on the Schedule for
the Assessment of Negative Symptoms)
23 and neuropsy-
chological impairment (defined as 2 standard deviations
below normal in one cognitive domain,and at least 1 stan-
dard deviation below normal in a second cognitive
domain) in tests of attention, long-term verbal memory,
and executive function (eg,planning and abstraction).
These criteria are tentative and will require much
research for their refinement and validation.Eventually,
we assume that biological measures, such as structural
or dynamic brain abnormalities, will come to be incor-
porated into the diagnosis. Tsuang’s initial criteria for
schizotaxia also required subjects to:(i) be first-degree
relatives of patients with schizophrenia;(ii) speak Eng-
lish as a first language;(iii) have estimated IQ scores of
at least 70; (iv) be between 19 and 50 years of age (the
age range was partly related to administration of a
treatment); and (v) provide informed consent to par-
ticipate. Exclusion criteria were designed to minimize
the influence of comorbid neurological, psychiatric, or
other medical conditions (eg,head injuries,current sub-
stance abuse, or history of electroconvulsive treat-
ments) that could mimic symptoms of schizotaxia.Indi-
viduals with any lifetime history of psychosis were
excluded from the study.
Validation of the syndrome
The subjects described above also received several
clinical interviews and rating scales in addition to tests
and ratings for schizotaxia.This allowed us to begin to
assess the concurrent validity of schizotaxia.
24 These
additional measures included the Quality of Life
(QOL) scale, the Social Adjustment Scale (SAS), the
Symptom Checklist-90-Revised (SCL-90), the Physi-
cal Anhedonia (PA) scale, and the Global Assessment
of Functioning (GAF) scale.The SAS,SCL-90,and PA
scale were all self-rated, while the QOL and GAF
scales were rated by the investigators. The investiga-
tor ratings were obtained blindly, as each subject’s
group assignment (schizotaxic or nonschizotaxic) was
made later, after the independent criteria for schizo-
taxia were evaluated. Twenty-seven people received
full evaluations for schizotaxia in the pilot study, of
whom 19 did not meet criteria and 8 did.Performance
on these supplementary scales was assessed by com-
paring subjects who met criteria for schizotaxia with
those who did not. For both self- and investigator-
rated scales, schizotaxic subjects showed consistently
poorer clinical or social function in a variety of areas.
They rated themselves as significantly more anhedonic
on the PA scale than did the nonschizotaxic subjects.
Schizotaxic subjects also showed a significantly higher
global severity index on the SCL-90, and demon-
strated particular elevations on the obsessive-compul-
sive, anxiety, and hostility subscales (other subscales,
such as depression, paranoia, and psychoticism, did
not differ between groups).Moreover,schizotaxic sub-
jects rated themselves as significantly more impaired
on several dimensions of social adjustment, as shown
by lower scores on the family attachment factor of the
SAS, and higher scores on the anxious ruminations
factor.Consistent with these findings,schizotaxic sub-
jects received significantly lower total ratings on the
QOL scale, including the interpersonal relations sub-
scale, and on the GAF scale. Because these findings
show that schizotaxia is associated with independent
measures of clinical and social function,they provide a
measure of concurrent validity for our specific diag-
nostic criteria.
Clinical research
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spectrum disorders
Like schizophrenia, the schizophrenia spectrum disor-
ders consist,to some degree,of a combination of the lia-
bility to schizophrenia (schizotaxia) and additional
symptoms (eg, psychosis). Treatment, therefore, must
address each of these components.This section will focus
mainly on milder spectrum disorders,including SPD and
schizotaxia, after a brief consideration of more severe
conditions.
Psychotic disorders
Treatments for schizoaffective disorder are the same
as those for schizophrenia and affective disorders
alone. Due to the heterogeneous nature of schizoaf-
fective disorder,we have found it useful to consider its
psychopharmacological treatment in terms of its puta-
tive subtypes, including the affective (or bipolar) sub-
type, and the schizophrenic (or unipolar) subtype.
Even with this division,the subtypes are probably not
“pure,” and are likely to include patients with related
disorders. Schizoaffective disorder, affective type, is
likely to include, in addition to patients with the cor-
rect diagnosis, some with bipolar affective disorder
and some in excited states of schizophrenia.For these
cases,treatment may include antipsychotic medication
(eg, clozapine, risperidone, or olanzapine) and, possi-
bly, mood stabilizers (eg, lithium) or anticonvulsants
(eg, valproate or carbamazepine). It will be necessary
in such cases to weigh the potential risks of such med-
ications,such as elevated toxicity,against the potential
benefits.
Treatment during intermorbid periods depends on the
presence or absence of psychotic symptoms. Psychotic
episodes in this period are associated with relatively
poorer outcomes, and are likely to require chronic
antipsychotic therapy.
Like the affective subtype, the schizophrenic subtype
of schizoaffective disorder probably represents a com-
bination of groups, including those with the correct
diagnosis, along with some patients with a psychotic
affective disorder,some patients with depressive forms
of schizophrenia,some patients with bipolar disorder,
and some patients with other conditions. Here again,
combination treatments are likely to be more effec-
tive than a single treatment in these patients.
Nonpsychotic disorders
Schizotypal personality disorder
Although several personality disorders (PDs) may be
related to the schizophrenia spectrum, including
schizoid, paranoid, and schizotypal personality disor-
ders, we focus on SPD because family studies show its
genetic basis more clearly than they do in the other two
conditions.
25,26 Some general therapeutic issues will be
considered,followed by a review of outcome studies.
Patients with SPD often chronically view the world as
an odd and threatening place, and thus may require
extended courses of treatment.
27-29 Unfortunately, trust
and rapport with the therapist—which are necessary for
the success of any psychosocial therapy—are often dif-
ficult to establish.The frequent occurrence of paranoia
and suspiciousness, together with social aloofness and
constricted affect,make exploratory psychotherapeutic
approaches less likely to bring about positive changes
than approaches that emphasize supportive and cogni-
tive–behavioral therapies.
27,29 In fact,these patients may
only seek treatment to alleviate circumscribed prob-
lems, like anxiety or somatic complaints.Approaches
that emphasize concrete, interim goals, and stipulate
explicit means of attaining them, thus have the best
chances of success. Because patients with SPD are vul-
nerable to decompensation during times of stress and
may experience transient episodes of psychosis, they
may also benefit from techniques to facilitate stress
reduction (eg,relaxation techniques,exercise,yoga,and
meditation). Fortunately, there is evidence that at least
some individuals with schizotypal features are likely to
seek treatment in times of stress.
30 In the short term,
brief courses of antipsychotic treatment may be useful
if symptoms of psychosis appear.
Because cognitive problems are also frequently amenable
to concrete,goal-oriented approaches to treatment,SPD
patients benefit from an understanding of their cognitive
strengths and weaknesses,to help them confront and cope
with long-standing difficulties in their lives.For example,
problems in attention, verbal memory, or organizational
skills contribute to failures in educational, occupational,
and social endeavors, while reinforcing negative self-
images and increasing performance anxiety. Knowledge
of circumscribed cognitive problems allows patients to
reframe their difficulties in a more positive manner, and
facilitate selection of more realistic personal,educational,
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387and occupational goals. Moreover, specific cognitive
deficits are often subject to at least partial remediation.
For example,standard procedures are available to atten-
uate deficits in the acquisition,organization,and retrieval
of new information (eg, writing information down in a
notebook, using appointment books or planners, and
rehearsing new information). Distractibility can be
reduced by focusing on one task at a time, in contrast to
switching back and forth between activities.
The value of specific treatments for psychiatric symp-
toms, however, is less clear, owing to a dearth of out-
come studies involving psychotherapy, psychosocial, or
psychopharmacological treatments for SPD. Published
studies show methodological limitations (eg,small sam-
ples,subjects with mixed diagnoses,inadequate controls,
and problems with internal validity), or provide out-
come data on only limited aspects of the disorder.Nev-
ertheless,it is clear that few treatment gains are evident
from recent studies, which serves to reaffirm both the
chronicity and the complexity of the disorder. This is
particularly true of studies that utilized psychodynami-
cally oriented therapy, either alone or in combination
with other treatments (eg,group therapy or art therapy)
as the primary treatment modality.
For example, McGlashan
31 studied former inpatients
approximately 15 years after treatment,who were given
retrospective DSM-III diagnoses.The study followed up
former patients with a variety of diagnoses, including,
among others,one third with pure SPD (n=10).Multiple
outcome measures were employed. Because the main
purpose of the study was to examine SPD as a diagnos-
tic entity, there was little emphasis on assessing change
in the same measures, which complicates any interpre-
tation.The results showed, however, that most subjects
with pure SPD functioned poorly at follow-up. On one
measure of global functioning in which 0=continuously
disabled and 4=normal,the mean score was 1.6.
Several studies investigated the usefulness of medica-
tions in treating SPD, although most investigations
employed small numbers of subjects and combined sam-
ples of schizotypal and borderline PDs.
32,33 For these rea-
sons, conclusions about the effectiveness of treatment
must be conservative. Those studies in which results
were reported for SPD separately from other PDs will
be emphasized. Typical antipsychotic drugs have been
proposed to reduce positive symptoms or depressed
mood in times of acute stress, but the high incidence of
adverse side effects has discouraged their widespread
use at other times, including the more chronic, stable
(ie, noncrisis) phases of the disorder.
27,32,34 Other types
of medication, including fluoxetine,
35 have generally
shown nonspecific effects.
Amoxipine, which has antidepressant and neuroleptic
effects,was administered to a small group of personality-
disordered patients that included 5 subjects diagnosed
with DSM-III SPD.
36After an average treatment duration
of 39 days, significant reductions were evident in total
scores on the Brief Psychiatric Rating Scale, and on the
Hamilton Rating Scale for Depression. The authors
hypothesized that the positive changes in this group were
due to the neuroleptic properties of the medication.
Goldberg et al
37 administered thiothixene (an antipsy-
chotic medication) to a group of patients that included,
among others,DSM-III SPD (n=6).The Global Assess-
ment Scale (GAS) and Hopkins Symptom CheckList-90
(HSCL-90) were among the measures used to assess
treatment effects.At the end of 12 weeks of treatment,
little therapeutic change was evident within the schizo-
typal groups, but modest improvements were observed
in particular areas across groups, such as the psychotic
and obsessive-compulsive scales of the HSCL-90.
Hymowitz et al
38 administered a low dose of haloperidol
to 17 outpatients with DSM-III diagnoses of SPD, for 6
weeks.The initial dose of 2.0 mg was intended to rise to
12.0 mg,but side effects prevented administration of such
a large increase, and the mean dose was 3.6 mg. Even
with lower doses, 50% of the sample withdrew from the
study because of side effects.Data analysis was performed
on all 17 subjects when they had completed just 2 weeks
of the protocol. Modest improvements were noted in
some subscales of the Schedule for Interviewing Border-
lines related to schizotypy (ie, ideas of reference, odd
communications,and social isolation) and on GAS scores.
Taken together, the available literature on treatments
for SPD offers few clearly effective treatments. The
mechanisms of the few treatments that were somewhat
effective are unknown. Interestingly, improvements in
types of symptoms (eg, psychoticism) across diagnoses,
rather than within them,
37 are consistent with the possi-
bility that they may help at least some subgroups of
patients.However,more psychopharmacological research
is needed in this area, with larger, more homogeneous
samples, to test the latter hypothesis. A review of the
medications used in these studies also makes clear a
need to find treatments that are well tolerated,and that
target negative symptoms and cognitive deficits.
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relation to treatment strategies for schizotaxia.
Schizotaxia
The general therapeutic considerations discussed above
in relation to SPD are relevant to schizotaxia as well.
Because schizotaxia is related biologically to schizo-
phrenia, we considered the possibility that effective
treatments for schizophrenia would also be of value in
schizotaxia. In particular, we hypothesized that schizo-
taxic deficits should respond to risperidone,a medication
that improves negative symptoms and neuropsycholog-
ical dysfunction in schizophrenic patients (see,for exam-
ple, references 39 and 40).Thus, we completed an open
drug trial in a small series of patients.
The clinical criteria for inclusion in the drug trial are
described above.
21 Individuals who met these criteria
for schizotaxia and who provided informed consent
received low doses of risperidone (0.25-2.0 mg) for 6
weeks. Side effects were temporary and mainly mild.
Five out of 6 individuals showed marked improvements
in attention,and mild-to-moderate reductions in nega-
tive symptoms.The sixth subject did not show improve-
ment in either area.This subject also differed from the
other cases in other ways. In particular, her level of
overall cognitive ability was below normal (estimated
IQ=75), raising the possibility that treatments might
be less effective when the ability to utilize them falls
below certain levels (the IQs of the other subjects
ranged between 92 and 111).The cognitive and clinical
improvements in 5 out of 6 individuals are encouraging
and provide support for larger, more controlled trials.
These preliminary findings are potentially important
for several reasons.First,they suggest that several key
clinical and neuropsychological symptoms in schizo-
taxic, first-degree relatives of patients with schizo-
phrenia are reversible, at least in part. Moreover, they
are reversible by a treatment that is effective against
some of the same symptoms in schizophrenia, consis-
tent with the view that these clinical symptoms may
reflect elements that are common to schizophrenia.
Second,they show that impairments in such individuals
may be ameliorated safely with risperidone. These
results are preliminary and require replication in
larger, controlled studies before they can be consid-
ered as a basis for treatment.Such studies are currently
in progress.
Future directions
Because the familial basis of schizophrenia spectrum
disorders reflects a genetic relationship to schizophre-
nia,we might predict that current,effective treatments
for schizophrenia would also be useful in the treatment
of these disorders. Moreover, family studies of schizo-
taxia suggest at least three pertinent directions for
future research. First, our initial findings with risperi-
done treatment suggests that pharmacological treat-
ments for spectrum disorders need not be limited to
periods of crisis and decompensation, but could also
be aimed at the chronic components of the disorders as
well.Second,schizophrenic illness is not limited to pos-
itive symptoms, but includes negative symptoms, neu-
ropsychological deficits, and neurobiological abnor-
malities. Consequently, treatment strategies need to
determine whether these symptoms are treatable.Our
findings with risperidone in schizotaxic relatives sug-
gest that at least some of these symptoms can be atten-
uated.Third,and perhaps most significantly,treatments
for schizotaxia have the potential to attenuate or even
prevent the development of other, more severe, disor-
ders in the spectrum of schizophrenia. An important
goal for the near future is the need to characterize and
validate schizotaxia as a syndrome. Eventually, how-
ever,treatments for schizotaxia might be administered
to high-risk individuals to prevent the onset of nonpsy-
chotic spectrum conditions and schizophrenia itself. ❑
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Estudios familiares y tratamiento del
espectro esquizofrénico
Una parte sustancial de la contribución de los
estudios genéticos al tratamiento de la esquizo-
frenia se refiere al énfasis en la confiabilidad y
validez del diagnóstico. Una consecuencia de este
enfoque es reconocer que la enfermedad esqui-
zofrénica es más amplia que la entidad diagnós-
tica de la esquizofrenia como tal, y más bien con-
siste en un “espectro” de trastornos relacionados.
Ya que algunos de los síntomas de estos trastor-
nos difieren unos de otros, ellos dan la oportuni-
dad de determinar cuáles reflejan una etiología
común. En la medida que estos síntomas sean
identificables, ellos podrán aportar un funda-
mento al tratamiento e incluso estrategias de pre-
vención. En este artículo nos enfocamos en una
condición clínica – “la esquizotaxia” – la que
puede reflejar el riesgo para la esquizofrenia.
Para caracterizar la naturaleza y dimensión de
este síndrome propuesto se revisarán los resulta-
dos de estudios familiares en nuestro laboratorio
y las bases conceptuales y criterios de evaluación.
Se continuará con una consideración más general
acerca de las estrategias terapéuticas del espectro
esquizofrénico junto con sugerencias para futuras
investigaciones. Nuestros intentos iniciales para
tratar y validar la esquizotaxia son alentadores y
auguran posibilidades que el tratamiento precoz
pueda eventualmente prevenir o atenuar otros
trastornos más severos del espectro esquizofréni-
co, incluida la esquizofrenia propiamente tal. 
Études familiales et traitement du spectre
des désordres associés à la schizophrénie
Les études génétiques participent de façon impor-
tante au traitement de la schizophrénie en contri-
buant à l’établissement d’un diagnostic sérieux et
valide. Ceci entraîne la reconnaissance que la
pathologie schizophrénique dépasse largement le
cadre de l’entité diagnostique de la schizophrénie
elle-même, pour inclure tout un spectre de
désordres associés. Du fait que ces désordres entraî-
nent des symptômes dont certains présentent des
différences nettes les uns par rapport aux autres, il
est possible de déterminer lesquels reflètent une
étiologie commune. Dans la mesure où ces symp-
tômes sont identifiables, ils peuvent servir de base
à des stratégies thérapeutiques ou même préven-
tives. Dans cet article nous nous sommes essentiel-
lement intéressés à un état clinique, “la schizo-
taxie”, qui pourrait traduire la prédisposition à la
schizophrénie. Dans le but de caractériser la natu-
re et l’étendue du syndrome ainsi défini, nous exa-
minerons les résultats provenant d’études fami-
liales effectuées dans notre laboratoire, tout en
évoquant quelles en sont les bases conceptuelles et
les critères d’évaluation. Suivront des considéra-
tions plus générales sur les stratégies thérapeu-
tiques concernant les désordres appartenant au
spectre de la schizophrénie ainsi que des proposi-
tions pour la recherche future. Nos premiers essais
concernant le traitement et la validation de la schi-
zotaxie sont encourageants et suggèrent qu'il est
possible, grâce au  traitement précoce, d'atténuer,
voire de prévenir le développement d'autres
désordres plus sévères appartenant au spectre de
la schizophrénie, voire la schizophrénie elle-même.
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